Last update Oct. 17, 2024

Miglitol

Compatible

Safe product and/or breastfeeding is the best option.

It is an alpha-glucosidase inhibitor that acts within the gastrointestinal tract without being absorbed by decreasing intestinal glucose absorption. Very low risk of hypoglycaemia in monotherapy. Oral administration 3 times daily

Miglitol is eliminated in breast milk in very small quantities (Serrano 2014, Pfizer 2012, AEMPS 2009), reaching a relative dose of well below 1%.

Diet, exercise and breastfeeding improve blood glucose levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Miglitol in other languages or writings:

Groups

Miglitol belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Miglitol in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 - 70 %
Molecular weight 207 daltons
Protein Binding < 4 %
VD 0.18 l/Kg
pKa 5.9 -
Tmax 2 - 3 hours
T½ 2 - 3 hours
Relative Dose 0.2 %

References

  1. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract

Total visits

6,627

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM